Phenomenex Expands Chiral Screening and Separation Power
Product News Feb 10, 2016
Phenomenex announces the addition of a 3µm particle size to the company’s newest chiral selector, Lux Amylose-1, amylose tris (3,5-dimethylphenylcarbamate). These high-efficiency Lux polysaccharide columns are ideal for UHPLC, HPLC and SFC chiral screening and analysis, and now with two sizes – the new 3µm and existing 5µm particles – method scalability from analytical work to preparative purification is seamless.
“Our six complementary and highly enantioselective Lux chiral stationary phases in both 3µm and 5µm sizes greatly enhance our customers’ potential for baseline enantiomeric separation,” explained Simon Lomas, strategic marketing manager for Phenomenex. “The Lux 3µm Amylose-1 in particular is an essential chiral screening phase, delivering increased separation power with its broad recognition and high efficiency levels.”
The affordable Lux Amylose-1 provides valuable enantioselectivity and is a guaranteed alternative to other phases with the same chiral selector. The 3µm-particle media is available in analytical columns while the 5µm-particle media is available in both analytical columns and Phenomenex-patented Axia™ preparative column hardware, both of which are stable in normal phase, reversed phase, polar organic and SFC conditions.
The Phenomenex Lux amylose and cellulose chiral column line of six chiral selectors comprise an affordable and complementary kit for chiral separations, featuring high efficiency, excellent loading capacity and pressure stability up to 300 bar in a wide range of conditions. Ideal applications for Lux columns include drug enantiomers from the pharmaceutical sector, chiral pesticide analysis in agrochemical settings, flavor analysis and production from the food industry, fragrance isolation and commercialization in cosmetics and a range of other chiral-chemical raw materials such as intermediates and finished goods.
To complement its comprehensive Lux chiral column line, Phenomenex offers free chiral screening services with greater than 90 percent success rates from its PhenoLogix application development group, along with over 2,000 chiral applications online that are easily searchable by compound structure or name.